NT
NTBLQ.US Notable Labs, Ltd.
- Market cap
- USD 96.00
- P/E
- -
- P/B
- -
- ROE
- -250.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2024.
Is NTBLQ.US undervalued?
Graham numberThe Graham number of Notable Labs, Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Notable Labs, Ltd. fundamental analysis
No fundamental analysis for Notable Labs, Ltd. yet.
Notable Labs, Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Notable Labs, Ltd.
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive medicines for patients with cancer. The company, through its proprietary Predictive Medicines Platform (PMP), bio-simulates a patient's cancer treatment and predicts whether patient will clinically respond to their actual treatment. Its PMP is designed to identify and select patients expected to be clinically responsive prior to the initiation of their treatment and enable fast-track ther…
Full company profileNotable Labs, Ltd. financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Notable Labs, Ltd. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 285K | 8.00K | 310K | 6.00K |
| Gross Profit | 285K | 8.00K | 113K | 6.00K |
| Operating Income | -16.9M | -12.9M | -14.7M | -18.4M |
| EBITDA | -16.6M | -12.6M | -14.4M | - |
| Net Income | -16.1M | -14.4M | -11.3M | -18.0M |
| EPS | -1.80 | -1.61 | -1.25 | -1.86 |
| Balance Sheet | ||||
| Total Assets | 8.49M | 5.51M | 19.5M | 11.0M |
| Total Liabilities | 62.4M | 42.5M | 4.43M | 3.82M |
| Shareholders' Equity | -53.9M | -37.0M | 15.1M | 7.19M |
| Cash & Short-term Investments | 2.40M | 1.58M | 11.8M | 4.09M |
| Cash Flow | ||||
| Operating Cash Flow | -15.1M | -11.6M | -13.7M | -14.5M |
| Capital Expenditure | 441K | 41.0K | 65.0K | 30.0K |
| Free Cash Flow | -15.5M | -11.7M | -13.8M | -14.6M |
| Ratios | ||||
| ROE | - | - | -74.5% | -250.1% |
| ROA | -189.1% | -261.4% | -57.6% | -163.3% |
| Net Profit Margin | -5,632.3% | -180,087.5% | -3,633.5% | -299,500.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Notable Labs, Ltd. dividends
Notable Labs, Ltd. has not paid dividends in the last 3 fiscal years.
Last stock split: 1:35 on Oct 17, 2023.
Who owns Notable Labs, Ltd.
Ownership data of Notable Labs, Ltd. is not available yet.
Notable Labs, Ltd. company profile
- Company name
- Notable Labs, Ltd.
- Ticker
- NTBLQ.US
- ISIN
- IL0012002452
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Fiscal year end
- December
- Address
- 320 Hatch Drive, Foster City, CA, United States, 94404
- Phone
- 415 851 2410
- Website
- notablelabs.com
About Notable Labs, Ltd.
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive medicines for patients with cancer. The company, through its proprietary Predictive Medicines Platform (PMP), bio-simulates a patient's cancer treatment and predicts whether patient will clinically respond to their actual treatment. Its PMP is designed to identify and select patients expected to be clinically responsive prior to the initiation of their treatment and enable fast-track therapeutic development in this patient population. The company's lead product is Volasertib, a polo like kinase 1 inhibitor to induce cell cycle arrest and apoptosis in various cancer cells. It is also developing two candidate predictive medicines and clinical-stage candidates for development in platform-predicted responders with acute myeloid leukemia. The company is based in Foster City, California. On October 13, 2024, Notable Labs, Ltd. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Notable Labs, Ltd. management
4- Mr. Scott Alan McPherson CFE, CPA, CVAChief Financial Officer · born 1961
- Dr. Joseph P. Wagner Ph.D.Chief Scientific Officer · born 1968
- Ms. Kaile ZaggerInterim CEO & Chief Restructuring Officer · born 1981
- Dr. Glenn C. Michelson M.D.Chief Medical Officer